FINAL HOURS: Lock in your InvestingPro subscription for 50% off before sale ends
Andrew D. Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), a prominent biotechnology company with $28.8 billion in revenue and strong financial health according to InvestingPro analysis, recently sold 2,500 shares of the company’s common stock. The transaction, executed on April 15, 2025, was made at a price of $106.40 per share, totaling approximately $266,000. This sale was conducted under a Rule 10b5-1 trading plan, which was adopted on August 29, 2024. The stock has shown impressive performance, delivering a 62.9% return over the past year, while maintaining relatively low price volatility. Following this transaction, Dickinson holds 168,174 shares of Gilead stock. According to InvestingPro analysis, the stock is currently trading near its Fair Value, with 12 more exclusive insights available to subscribers.
In other recent news, Gilead Sciences has been the focus of several analyst reports, particularly concerning its HIV prevention treatments. Citi analysts have reiterated a Buy rating with a $125 price target, expressing confidence in Gilead’s pre-exposure prophylaxis (PrEP) business despite potential federal funding cuts. They highlight the predominantly commercial nature of the PrEP market, suggesting limited impact from government funding changes. Meanwhile, BMO Capital Markets maintained an Outperform rating with a $115 target, noting that while funding cuts may pose risks, the overall effect on Gilead’s PrEP franchise should be modest.
Bernstein analysts also upheld an Outperform rating with a $120 target, driven by optimism for Gilead’s upcoming HIV prevention treatment, lenacapavir. This treatment is expected to significantly enhance patient adherence and market penetration. In another development, Gilead Sciences announced the departure of Sandra Patterson, its Senior Vice President, Corporate Controller, and Chief Accounting Officer, with Diane E. Wilfong stepping in as the interim replacement. Investors are closely monitoring these developments, especially in light of potential policy changes regarding federal HIV funding, which could impact Gilead and similar companies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.